PlainPharmaWatch

CMS Open Payments · Program Year 2024

Bard Peripheral Vascular, Inc.

Bard Peripheral Vascular, Inc. reported $6,519,561.49 across General Payments, Research, and Ownership to 8,034 physicians and teaching hospitals across 8,183 transactions.

See the rankings → How this is sourced
$6.5M Top quartile payer
All-tracks total
8,183 Top quartile volume
Transactions
8,034 Top quartile reach
Recipients
+$471.1K
General Payments vs PY2023

Bard Peripheral Vascular, Inc. reported $6,519,561.49 across all CMS Open Payments tracks (General + Research + Ownership) to 8,034 physicians and teaching hospitals in Program Year 2024 - ranking #229 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,565,271.95, averaging $811.50 per recipient.

How Bard Peripheral Vascular, Inc.'s $6.5M all-tracks total breaks down

Bard Peripheral Vascular, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

C

78/100

Total payments

C

70/100

Transaction volume

C

70/100

Physician reach

C

71/100

Payment type diversity

A

100/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer bard-peripheral-vascular-inc Bard Peripheral Vascular, Inc.

$6.5M · #229/1,925 · 0.0% industry · PY2024

  • TOT $6.5M
  • RANK #229
  • SHARE 0.0%
  • TXN 8,183
  • RCP 8,034
  • CAT 9
  • GEN $4.6M
  • ΔGEN +$471.1K
  • TOP1 51.6%
  • PY 2024

Volume peers

Nearest volume peer: Convergent Dental Inc. ($6.5M)

Arcutis Biotherapeutics, Inc.$6.6MBard Peripheral Vascular, In…$6.5MConvergent Dental Inc.$6.5MMylan Inc.$6.4MBaxter Healthcare$6.4M
All-tracks payment totals near Bard Peripheral Vascular, Inc. (CMS Open Payments PY2024)

Bard Peripheral Vascular, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Bard Peripheral Vascular, Inc.'s CMS-reported General Payments increased by $471.1K (+11.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BARD PERIPHERAL VASCULAR, INC.PY2023: BARD PERIPHERAL VASCULAR, INC.PY2024: Bard Peripheral Vascular, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$4.1MPY2024$4.6M
PY2023
$4,094,205.85
PY2024
$4,565,271.95

What the Data Shows for Bard Peripheral Vascular, Inc.

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Bard Peripheral Vascular, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

The 9-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $2.4M, accounting for 52.4% of this company's General Payments and 5 transactions.

General Payment Breakdown by Type

Across 9 types of general payments, Bard Peripheral Vascular, Inc.'s largest category was "Royalty or License" at $2.4M - 52.4% of General Payments.

Bard Peripheral Vascular, Inc. reports 9 general-payment categories - the top three are Royalty or License (52.4%), Consulting Fee (26.3%), and Food and Beverage (7.2%). The remaining 6 categories make up 14.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Bard Peripheral Vascular, Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Bard Peripheral Vascular, Inc. divides its payments

Ranked by total dollars reported per category

1. Royalty or License$2.4M2. Consulting Fee$1.2M3. Food and Beverage$330.8K4. Debt Forgiveness$195.1K5. Travel and Lodging$186.6K6. Honoraria$111.4K7. Education$91.1K8. Long-Term Medical Supply …$53.9K9. Grant$5.0K
Payment Type Amount Transactions
Royalty or License $2.4M 5
Consulting Fee $1.2M 447
Food and Beverage $330.8K 6,930
Debt Forgiveness $195.1K 6
Travel and Lodging $186.6K 494
Honoraria $111.4K 65
Education $91.1K 64
Long-Term Medical Supply or Device Loan $53.9K 22
Grant $5.0K 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $2,716,395.30 (59.5%) of $4,565,271.95 in this company's General Payments records across 3,863 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Bard Peripheral Vascular, Inc.

The five named recipients with the highest reported General Payments from this company

Richard Chesbrough$2.4MWadley Regional Medical Cent…$168.7KRobert Lewandowski$64.4KZiv Haskal$63.9KRiad Salem$63.2K
  1. 1

    Richard Chesbrough

    $2,356,281.00 across 4 reported transactions

  2. 2

    Wadley Regional Medical Center

    $168,680.19 across 1 reported transactions

  3. 3

    Robert Lewandowski

    $64,418.30 across 21 reported transactions

  4. 4

    Ziv Haskal

    $63,865.29 across 16 reported transactions

  5. 5

    Riad Salem

    $63,150.52 across 33 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Bard Peripheral Vascular, Inc. ranks #229 of 1,925 by total payments (top 12% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #616 of 1,838 by HHI (top 34% most concentrated), a wider distribution than most similarly sized payers.

01.32.63.95.32658.32678.42698.52718.62738.7Total payments ($M)Concentration (HHI, 0-10,000)
Bard Peripheral Vascular, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Bard Peripheral Vascular, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Bard Peripheral Vascular, Inc..

Vitrolife Inc.

HHI 2698

Eisai Co., Ltd.

HHI 2691

Bonebridge Inc.

HHI 2676

Dentsply Sirona Orthodontics Inc

HHI 2714

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Bard Peripheral Vascular, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Bard Peripheral Vascular, Inc. ranks #229 of 1,925 by all-tracks total payments, led by "Royalty or License".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Bard Peripheral Vascular, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.